Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZOM Stock Forecast 2025-2026
$0.06
Current Price
$95.35M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ZOM Price Targets
+354.5%
To High Target of $0.25
+354.5%
To Median Target of $0.25
+354.5%
To Low Target of $0.25
ZOM Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-72.2%
1 Year Change
-58.3%
Year-to-Date Change
-71.8%
From 52W High of $0.20
+264.2%
From 52W Low of $0.02
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Zomedica (ZOM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ZOM and similar high-potential opportunities.
Latest ZOM Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ZOM has a bullish consensus with a median price target of $0.25 (ranging from $0.25 to $0.25). Currently trading at $0.06, the median forecast implies a 354.5% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZOM Analyst Ratings
1
Buy
0
Hold
0
Sell
ZOM Price Target Range
Low
$0.25
Average
$0.25
High
$0.25
Current: $0.06
Latest ZOM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZOM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 6, 2023 | Dawson James | Jason Kolbert | Buy | Initiates | $6.00 |
| Nov 16, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.30 | |
| Jun 17, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.50 |
Zomedica Corp. (ZOM) Competitors
The following stocks are similar to Zomedica based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zomedica Corp. (ZOM) Financial Data
Zomedica Corp. has a market capitalization of $95.35M with a P/E ratio of 0.0x. The company generates $26.73M in trailing twelve-month revenue with a -232.7% profit margin.
Revenue growth is +10.2% quarter-over-quarter, while maintaining an operating margin of -106.3% and return on equity of -26.8%.
Valuation Metrics
Market Cap
$95.35M
Enterprise Value
$20.55M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+10.2%
Gross Margin
+70.3%
Operating Margin
-106.3%
Net Margin
-232.7%
EPS Growth
+7.6%
Financial Health
Cash/Price Ratio
+141.8%
Current Ratio
10.8x
Debt/Equity
1.0x
ROE
-26.8%
ROA
-9.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Zomedica Corp. (ZOM) Business Model
About Zomedica Corp.
What They Do
Develops veterinary diagnostic and therapeutic products.
Business Model
Zomedica Corp. generates revenue by creating and selling innovative diagnostic and therapeutic products aimed at improving veterinary care for companion animals. Their offerings include advanced point-of-care diagnostic platforms, remote monitoring systems, and therapeutic devices that cater to the specific needs of clinical veterinarians.
Additional Information
The company collaborates with Celsee, Inc. and Seraph Biosciences, Inc. to enhance its product lineup with liquid biopsy assays for cancer detection and pathogen detection systems. Founded as Zomedica Pharmaceuticals Corp., it rebranded to Zomedica Corp. in October 2020 and is based in Ann Arbor, Michigan.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
144
CEO
Mr. Larry C. Heaton II
Country
United States
IPO Year
2017
Website
www.zomedica.comZomedica Corp. (ZOM) Latest News & Analysis
Latest News
Quick Summary
NYSE American is initiating delisting proceedings for Zomedica Corp. (ZOM) due to non-compliance with listing standards, with immediate trading suspension.
Why It Matters
Delisting of Zomedica Corp. indicates financial instability, diminishing investor confidence, and potential loss of liquidity, negatively impacting stock value and investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Zomedica's shares will be delisted from NYSE American due to low prices and will begin trading on OTCQB under the ticker "ZOMDF" starting March 5, 2025.
Why It Matters
Zomedica's delisting from NYSE American and move to OTCQB indicates financial instability, potentially impacting liquidity and investor confidence in the company's future.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Zomedica Corp. (NYSE American: ZOM) will hold a conference call on March 13, 2025, at 4:30 p.m. ET to discuss its Q4 and full-year 2024 operational and financial highlights.
Why It Matters
Zomedica's upcoming conference call will provide insights into its Q4 and full-year financial performance, impacting stock valuation and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Zomedica Corp. has relocated its headquarters to a more efficient facility in Ann Arbor, reducing annual overhead by over $200,000, supporting its growth strategy.
Why It Matters
Zomedica's relocation to a more efficient facility reduces overhead costs significantly, enhancing profitability and indicating potential for growth, which could positively affect stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Zomedica Launches the TRUFORMA(R) Enhanced Endogenous ACTH Assay to aid in Equine PPID Diagnosis
3 months ago
Quick Summary
Zomedica Corp. announced an update to its TRUFORMA biosensor platform, enhancing its eACTH assay for equine plasma, the only point-of-care test for measuring eACTH in horses.
Why It Matters
Zomedica's TRUFORMA eACTH assay enhances its market position in veterinary diagnostics, potentially increasing revenue and attracting investor interest in the growing animal healthcare sector.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Zomedica Corp. has entered a license agreement with Cresilon to exclusively market Vetigel® hemostatic gel in the U.S. and non-exclusively abroad, enhancing its veterinary product offerings.
Why It Matters
Zomedica's exclusive license for Vetigel® enhances its product portfolio, potentially boosting revenue and market presence in veterinary care, which may attract investor interest.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About ZOM Stock
What is Zomedica Corp.'s (ZOM) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Zomedica Corp. (ZOM) has a median price target of $0.25. The highest price target is $0.25 and the lowest is $0.25.
Is ZOM stock a good investment in 2025?
According to current analyst ratings, ZOM has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZOM stock?
Wall Street analysts predict ZOM stock could reach $0.25 in the next 12 months. This represents a 354.5% increase from the current price of $0.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zomedica Corp.'s business model?
Zomedica Corp. generates revenue by creating and selling innovative diagnostic and therapeutic products aimed at improving veterinary care for companion animals. Their offerings include advanced point-of-care diagnostic platforms, remote monitoring systems, and therapeutic devices that cater to the specific needs of clinical veterinarians.
What is the highest forecasted price for ZOM Zomedica Corp.?
The highest price target for ZOM is $0.25 from at , which represents a 354.5% increase from the current price of $0.06.
What is the lowest forecasted price for ZOM Zomedica Corp.?
The lowest price target for ZOM is $0.25 from at , which represents a 354.5% increase from the current price of $0.06.
What is the overall ZOM consensus from analysts for Zomedica Corp.?
The overall analyst consensus for ZOM is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $0.25.
How accurate are ZOM stock price projections?
Stock price projections, including those for Zomedica Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 7:45 AM UTC